• Efficacy of Mastodinone® for mastalgia correction in pre- and perimenopausal women

Efficacy of Mastodinone® for mastalgia correction in pre- and perimenopausal women

HEALTH OF WOMAN. 2018.5(131):72–75

Rozhkova N. I. , Burdina I. I. , Zapirova S. B. , Mazo M. L. , Prokopenko S. P. , Yakobs O. E.
The National Center of Oncology of Reproductive Organs of the FSBU of the MNOI P.A. Hertsen, Moscow
Department of Clinical Mammology, Radiation Diagnostics and Radiation Therapy FPE PFUR, Moscow
Gynecology. 2016; 06: 28-31

The purpose of the study was to examine the effectiveness of the drug Mastodynon® for the treatment of mastopathy in pre- and perimenopausal women.

Materials and methods. The research was carried out within 12 months. Patient presenting complaints of pain in the breast, passed a comprehensive examination (clinical and Х-ray and/or sonographic) and questionnaires at the first visit and every 6 months. The plant-based drug Mastodynon®

Results. We examined 38 patients aged 45–56 years. Most women in this group for many years were observed due to mastopathy of different forms and degrees of severity. After 6 months after start of treatment with Mastodynon® the majority of patients reported decrease or absence of pain in the breasts, improvement of psycho-emotional condition. The positive effect of various degree was observed in 71.05% of the patients. After 1 year revealed a stabilization of the therapeutic effect of the drug Mastodynon® in 83.3% of cases. 

Mastodynon® has shown high effectiveness, good tolerability in the treatment of mastopathy in women of pre- and perimenopausal age, it has improved thepatients quality of life.

Key words: mastopathy, mastalgia, Mastodynon®.

REFERENCES

1. Burdina LM. 1993. Kliniko-rentgenologicheskie osobennosti zabolevanii molochnykh zhelez u ginekologicheskikh bol’nykh reproduktivnogo vozrasta s neiroendokrinnoi patologiei. Avtoref. dis. d-ra med. nauk. M.

2. Burdina LM. 1996. Osnovnye printsipy lecheniia diffuznykh dobrokachestvennykh patologicheskikh izmenenii molochnykh zhelez. Mammologiia 4:9–14.

3. Rozhkova NI, Burdina II. 2010. Kliniko-rentgeno-patomorfologicheskaia kharakteristika i lechenie diffuznykh dobrokachestvennykh zabolevanii molochnoi zhelezy (mastopatii). M:30.

4. Rozhkova NI, Burdina LM, Smetnik VP, Burdina II. 2008. Lekarstvennaya patogeneticheskaya korrektsiya dobrokachestvennykh zabolevaniy molochnoy zhelezy. Opukholi zhenskoy reproduktivnoy sistemy 2:48–54.

5. Rozhkova NI, Burdina II i dr. 2012. Diffuznye dobrokachestvennye zabolevaniya molochnoy zhelezy: diagnostika i lechenie. Pod red. Solodkogo VA, Rozhkovoy NI. M, SIMK:124.

6. Zaydieva YaZ, Balan VE. 2000. Primenenie fitoestrogenov dlya lecheniya gipoestrogennykh sostoyaniy. RMZh. 3:156.

7. Prior JC. 2011. Progesterone for symptomatic perimenopause treatment- progesteronepolitics, physiology and potencial for perimenopause. Facts Views Vis Obgyn 3(2):109–20. PMid:24753856 PMCid:PMC3987489

8. Samsioe G. 1996. Medical and surgical Strategies for treating urogynecological disorders. Int J Ferticl 41(2):139–41.

9. Mammologiya. Natsional’noe rukovodstvo. Pod red. Kaprina AD, Rozhkovoy NI. 2-e izd. M. 2016:311–15.

10. Sedakova IE, Aleksandrov AI, Denisenko YaV, Ishchenko RV. 2008. Opyt lecheniya pri mastopatii u zhenshchin v menopauze. Onkologiya 10(4):429–31.

11. Zaydieva YaZ. 1997. Gormonoprofilaktika sistemnykh narusheniy u zhenshchin v perimenopauze. Avtoref. dis. d-ra med. nauk. M.

12. Milewicz A, Gejdel E, Sworen H et al. 1993. Vitexagnuscastus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung 43(7):752–6. PMid:8369008

13. Jarry H, Leonardt S, Wunke W. 1991. Agnuskastusalsdopaminerges. Wirkprinzip in Mastodynon. N Ztsehr Phytother 12:77–82.

14. Hoberg E, Sticher O, Orjala JE, Meier B. 1999. Diterpene aus Fgni-castifructus und ihre Analytik. Ztsehr Phytother 149:3.

15. Sliutz G, Speiser P, Schultz AM. 1993. Agnus kastusextraksingibit prolactin secrecion of pituitery cell. Horm Metabol Res 25:243–55. https://doi.org/10.1055/s-2007-1002090; PMid:8330858

16. Wuttke W, Gorcow C, Jarry H. 1995. Dopaminergie compounds in Vitexagnuskastus. In the pub. Phytopharmaka in forschung und klinischerAnwendung.  Loew D, Rietbrock N (Hrsg). Darmstadt: Steinkopf: 81–91. https://doi.org/10.1007/978-3-642-85434-7_6; PMid:7553079

17. Sotnikova LS i dr. 2011. Sostoyanie gormonal’noy regulyatsii pri fibrozno-kistoznoy mastopatii. Mat’ i ditya 1:342–6.